Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Now, after 5 years of preparation and with the compliance deadline only weeks away, the lack of clarity around Brexit remains an obstacle for pharma companies operating on both sides of the Channel.

Brexit - the EU FMD's painful problem

So, what does Brexit mean for the FMD?

We ask industry leader - Daniel Tedham, Managing Director, Wasdell Manufacturing a division of the Wasdell Group - about the current state of the exit agreement, the possibility and problems of a ‘no deal’ and the impact on the UK and European pharmaceutical industries.

What will be the impact of Brexit on the FMD?

Tedham: “There is still a lot of uncertainty surrounding the impact that Brexit will have on the EU FMD regulations. The date for the UK’s exit from the EU is the 29 March 2019, meaning up until this date the UK will legally need to comply with all EU legislation including the EU FMD.

“The Medicines and Healthcare products Regulatory Agency (MHRA) has recently released guidance which outlines an implementation period between 30 March 2019 and 31 December 2020, during which time the UK pharmaceutical industry would continue to meet all EU FMD requirements while the UK authorities work to develop a system that will work alongside the EU’s.”

What are the implications of a ‘no-deal’ Brexit?

Tedham: “While the UK will still have its own Medicines Verification Systems – the UKMVS – it would also need continued access to the European Medicines Verification System (EMVS) to allow the FMD legislation to be fully effective. In the event of a ‘no-deal’ Brexit this is not guaranteed.

“The logistics of how this will work are not yet fully understood. The political fallout of a hard Brexit could potentially affect patient safety due to reduced access to vital medicines and delays in accessing critical information.”

What are companies doing to ensure operations are unaffected by Brexit?

Tedham: “Many UK-based companies have opted to create contingency plans, establishing a presence in the EU or forming partnerships with third parties to ensure sufficient resource for additional release testing requirements. At Wasdell, we are building a new facility in Dundalk, Ireland to ensure business continuity for our customers. We have also started to develop bespoke alterations to supply chains to ensure minimal impact, regardless of the outcome of Brexit negotiations.”

Read More

Related news

Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Brexit's trick or treat on patient safety

Brexit's trick or treat on patient safety

29 Apr 2019

Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.

Read more 
Surge of Indian biosimilars market forecast in 2019

Surge of Indian biosimilars market forecast in 2019

22 Apr 2019

India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.

Read more 
RAPS on delayed Brexit

RAPS on delayed Brexit

26 Mar 2019

The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.

Read more 
Sizeable growth potential for global drug delivery and packaging in 2019

Sizeable growth potential for global drug delivery and packaging in 2019

19 Mar 2019

Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.

Read more 
'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
All Recipharm facilities ready for EU serialisation, regardless of Brexit

All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Read more 
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Univercells introduces breakthrough vaccine manufacturing platform

Univercells introduces breakthrough vaccine manufacturing platform

13 Jan 2019

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Read more